Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1979 1
1982 1
1985 1
1986 2
1988 1
1990 3
1993 5
1994 1
1995 2
1997 3
1999 5
2000 3
2001 4
2002 4
2003 4
2004 4
2005 4
2006 5
2007 10
2008 8
2009 5
2010 5
2011 14
2012 16
2013 12
2014 12
2015 11
2016 6
2017 11
2018 12
2019 9
2020 15
2021 10
2022 3
2023 3
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

190 results

Results by year

Filters applied: . Clear all
Page 1
Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study.
Salem R, Johnson GE, Kim E, Riaz A, Bishay V, Boucher E, Fowers K, Lewandowski R, Padia SA. Salem R, et al. Hepatology. 2021 Nov;74(5):2342-2352. doi: 10.1002/hep.31819. Epub 2021 Jun 11. Hepatology. 2021. PMID: 33739462 Free PMC article.
BACKGROUND AND AIMS: Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unresectable HCC. ...Among the 162 patients included, 60.5% were Eastern Cooperative Oncology Group 0, and the median tumor size was 2.7 cm (rang …
BACKGROUND AND AIMS: Locoregional therapies, including yttrium-90 radioembolization, play an important role in the treatment of unres …
Fibrolamellar Hepatocellular Carcinoma: Comprehensive Review of Diagnosis, Imaging, and Management.
Aziz H, Brown ZJ, Panid Madani S, Kamel IR, Pawlik TM. Aziz H, et al. J Am Coll Surg. 2023 Feb 1;236(2):399-410. doi: 10.1097/XCS.0000000000000476. Epub 2022 Nov 4. J Am Coll Surg. 2023. PMID: 36648268
BACKGROUND: Fibrolamellar hepatocellular carcinoma (FLC) is a rare malignancy that primarily affects patients in late adolescence and young adulthood. ...The rarity of these tumors, coupled with the only recent acknowledgment of the genomic abnormality, has likely l …
BACKGROUND: Fibrolamellar hepatocellular carcinoma (FLC) is a rare malignancy that primarily affects patients in late adolesce …
Liver resection and transplantation in the management of hepatocellular carcinoma: a review.
Kassahun WT, Fangmann J, Harms J, Hauss J, Bartels M. Kassahun WT, et al. Exp Clin Transplant. 2006 Dec;4(2):549-58. Exp Clin Transplant. 2006. PMID: 17238857 Free article. Review.
Hepatocellular carcinoma (HCC) accounts for more than 80% of all primary liver cancers and is one of the most common malignancies worldwide. ...For that purpose, using ablative techniques or chemoembolization to control local tumor growth is useful....
Hepatocellular carcinoma (HCC) accounts for more than 80% of all primary liver cancers and is one of the most common malignanc …
Treatment and outcomes of recurrent hepatocellular carcinomas.
Joliat GR, Allemann P, Labgaa I, Demartines N, Halkic N. Joliat GR, et al. Langenbecks Arch Surg. 2017 Aug;402(5):737-744. doi: 10.1007/s00423-017-1582-9. Epub 2017 May 11. Langenbecks Arch Surg. 2017. PMID: 28497194
PURPOSE: Surgery is one of the best options for curative treatment of hepatocellular carcinomas (HCC). Recurrences are nevertheless common (45-75%). ...CONCLUSIONS: Recurrence after surgical HCC resection is frequent and negatively impacts OS. Interventional treatme …
PURPOSE: Surgery is one of the best options for curative treatment of hepatocellular carcinomas (HCC). Recurrences are nevertheless c …
Transarterial Chemoembolization in Treatment-Naive and Recurrent Hepatocellular Carcinoma: A Propensity-Matched Outcome Analysis.
Kim DS, Lim TS, Jeon MY, Kim BK, Park JY, Kim DY, Ahn SH, Han KH, Baatarkhuu O, Kim SU. Kim DS, et al. Dig Dis Sci. 2019 Dec;64(12):3660-3668. doi: 10.1007/s10620-019-05701-8. Epub 2019 Jun 11. Dig Dis Sci. 2019. PMID: 31187326
OBJECTIVES: Transarterial chemoembolization (TACE) improves the survival of patients with hepatocellular carcinoma (HCC); however, TACE treatment outcomes of patients with treatment-naive HCC (TN-HCC) and those with recurrent HCC after curative resection (R-H …
OBJECTIVES: Transarterial chemoembolization (TACE) improves the survival of patients with hepatocellular carcinoma (HCC); howe …
Trends and Patterns of Hepatocellular Carcinoma Treatment in Korea.
Hong YM, Yoon KT, Cho M, Kang DH, Kim HW, Choi CW, Park SB, Heo J, Woo HY, Lim W. Hong YM, et al. J Korean Med Sci. 2016 Mar;31(3):403-9. doi: 10.3346/jkms.2016.31.3.403. Epub 2016 Feb 17. J Korean Med Sci. 2016. PMID: 26955241 Free PMC article.
Multiple therapeutic modalities are available for hepatocellular carcinoma (HCC) treatment. ...The 3 most common treatment modalities (hepatic resection, local ablation therapy, TACE) used after initial treatment in 2009 were studied. ...
Multiple therapeutic modalities are available for hepatocellular carcinoma (HCC) treatment. ...The 3 most common treatm …
The Outcome of Salvage Liver Transplantation and Liver Resection for Recurrent Hepatocellular Carcinoma Using the 5-5-500 Rule, Japanese Extended Liver Transplantation Criteria for Hepatocellular Carcinoma.
Hirata Y, Kotera Y, Kato T, Ariizumi S, Kogiso T, Tokushige K, Honda G, Egawa H. Hirata Y, et al. Transplant Proc. 2023 May;55(4):901-905. doi: 10.1016/j.transproceed.2023.04.028. Epub 2023 May 25. Transplant Proc. 2023. PMID: 37244836
BACKGROUND: Liver transplantation (LT) for hepatocellular carcinoma (HCC) is limited to Child-Pugh class C patients according to the Japanese HCC treatment algorithm. However, extended criteria of LT for HCC, known as the 5-5-500 rule, were published in 2019. Hep …
BACKGROUND: Liver transplantation (LT) for hepatocellular carcinoma (HCC) is limited to Child-Pugh class C patients according …
Improvement of clinical management and outcome in hepatocellular carcinoma nowadays compared with historical cohorts.
Schellhaas B, Strobel D, Stumpf M, Ganslmayer M, Pfeifer L, Goertz RS, Neurath MF, Zopf S. Schellhaas B, et al. Eur J Gastroenterol Hepatol. 2018 Dec;30(12):1422-1427. doi: 10.1097/MEG.0000000000001221. Eur J Gastroenterol Hepatol. 2018. PMID: 30052538
OBJECTIVES: Therapeutic approaches in the treatment of hepatocellular carcinoma (HCC) depend on tumour stage, liver function and patient comorbidities. ...CONCLUSION: HCC is increasingly being diagnosed in earlier stages, so that single therapy is ofte …
OBJECTIVES: Therapeutic approaches in the treatment of hepatocellular carcinoma (HCC) depend on tumour stage, liver fun …
Combined hepatocellular carcinoma and cholangiocarcinoma: clinical features, treatment modalities, and prognosis.
Yin X, Zhang BH, Qiu SJ, Ren ZG, Zhou J, Chen XH, Zhou Y, Fan J. Yin X, et al. Ann Surg Oncol. 2012 Sep;19(9):2869-76. doi: 10.1245/s10434-012-2328-0. Epub 2012 Mar 27. Ann Surg Oncol. 2012. PMID: 22451237
BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer that has rarely been reported in large-scale clinical studies. ...Clinicopathologic features and prognosis of 103 cHCC-CC patients after liv …
BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma (cHCC-CC) is an uncommon subtype of primary liver cancer …
Hurthle Cell Carcinoma: Single Center Analysis and Considerations for Surgical Management Based on the Recent Literature.
Chiapponi C, Hartmann MJM, Schmidt M, Faust M, Bruns CJ, Schultheis AM, Alakus H. Chiapponi C, et al. Front Endocrinol (Lausanne). 2022 Jun 29;13:904986. doi: 10.3389/fendo.2022.904986. eCollection 2022. Front Endocrinol (Lausanne). 2022. PMID: 35846317 Free PMC article.
BACKGROUND: Hurthle cell carcinoma (HCC) of the thyroid is rare. There are contrasting data on its clinical behavior. ...Five (41.6%) patients developed metastatic disease, followed by systemic therapy in two patients. Vascular invasion of the primary tumor was sign …
BACKGROUND: Hurthle cell carcinoma (HCC) of the thyroid is rare. There are contrasting data on its clinical behavior. ...Five (41.6%) …
190 results